| Identifier |
20150223_nanos_journalclub1_02 |
| Title |
The Relationship Between PDE-5 Inhibitors and NAION |
| Creator |
Howard D. Pomeranz, MD |
| Affiliation |
North Shore Long Island Jewish Health System and Hofstra North Shore LIJ School of Medicine, Great Neck, NY |
| Subject |
Erectile Dysfunction Drug; Non-Arteritic Anterior Ischemic Optic Neuropathy; Phosphodiesterase 5 (PDE-5) Inhibitor; Pfizer; Sildenafil |
| History |
Sildenafil was first synthesized by pharmaceutical chemists working at Pfizer. It was initially studied for use in hypertension and angina. Phase I clinical trials suggested that the drug had little effect on angina but could induce penile erection. Sildenafil (Viagra®) was patented in 1996 and approved by the FDA for use in erectile dysfunction (ED) in March, 1998. Vardenafil (Levitra®) was approved by the FDA for treatment of erectile dysfunction in August, 2003 and tadalafil (Cialis®) in November, 2003. Avanafil (Stendra®) was approved in April, 2012. Udenafil (Zydena) is not FDA approved for sale in the United States, but is available in Korea, Russia and the Philippines. |
| Date |
2015-02 |
| Language |
eng |
| Format |
application/pdf |
| Type |
Text |
| Relation is Part of |
NANOS Annual Meeting Journal Club, 2015 |
| Collection |
Neuro-Ophthalmology Virtual Education Library - Walsh Session Annual Meeting Archives https://novel.utah.edu/Walsh/index3.html |
| Publisher |
Spencer S. Eccles Health Sciences Library, University of Utah |
| Holding Institution |
Spencer S. Eccles Health Sciences Library, University of Utah, 10 N 1900 E SLC, UT 84112-6232 |
| Rights Management |
Copyright 2015. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
| ARK |
ark:/87278/s6613wxq |
| Setname |
ehsl_novel_fbw |
| ID |
179289 |
| Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6613wxq |
